Gallant Secures $18M Series B for Pet Stem Cell Therapy Launch

Gallant, a biotechnology company based in San Diego, focuses on advancing veterinary regenerative medicine. The company has recently raised $18 million in Series B funding. Leading the investment was Digitalis Ventures, with substantial backing from BOLD Capital and Hill Creek Partners. New participation came from NovaQuest Capital Management, enhancing Gallant's financial support with their extensive experience in stem cell therapies approved by the FDA for human use.

Gallant is breaking new ground in veterinary healthcare with its ready-to-use stem cell therapies aimed at addressing root causes of prevalent diseases affecting dogs and cats. The company's pioneering work targets conditions that are currently underserved and poorly managed by existing treatments, such as Feline Chronic Gingivostomatitis (FCGS), Canine and Feline Osteoarthritis (COA and FOA), Canine Atopic Dermatitis (CAD), and Feline Chronic Kidney Disease (CKD).

Gallant's flagship product for treating refractory FCGS in cats is anticipated to receive conditional FDA approval by early 2026. This product could set a precedent as the first FDA-labeled allogeneic stem cell therapy in veterinary medicine. The new funding will expedite Gallant's commercial efforts for its FCGS treatment and further development of other therapeutic candidates in its pipeline.

Dr. Cindy Cole, Technical Partner at Digitalis Ventures, expressed her admiration for Gallant's innovative approach and the potential they hold to revolutionize animal healthcare. She highlighted the company's commitment to tackling persistent veterinary challenges with a technology platform that aims for genuine disease modification, not just symptom relief.

BOLD Capital's Managing Partner, Teymour Boutros-Ghali, underscored the significance of Gallant's progress and the excitement surrounding their potential FDA approval pathway toward market introduction. He emphasized the transformative potential of Gallant’s offerings in redefining what’s possible in veterinary care.

With NovaQuest joining the investment round, Gallant benefits from their proven track record in the stem cell therapy arena. NovaQuest's previous venture involvement includes the introduction of RYONCIL®, the first FDA-approved allogeneic mesenchymal stromal cell therapy for humans, marking a significant milestone in regenerative medicine. Brian Axe, a Partner at NovaQuest, highlighted the timely relevance and impact of bringing stem cell therapies to the veterinary field, emphasizing the promise of these treatments in addressing root causes of animal diseases.

Research by Gallant has identified a considerable gap in veterinary satisfaction with current treatments, especially noting that only 56% of vets are content with canine osteoarthritis therapies, and a mere 8% with FCGS options. Gallant's development efforts focus on providing veterinarians with new tools that not only alleviate symptoms but also tackle the diseases at their core—an approach well-aligned with the shifting interests of practitioners in regenerative medicine.

Dr. Linda Black, Gallant’s CEO, expressed appreciation for the support from their investment partners, acknowledging their shared vision of creating a new class of veterinary medicine that provides lasting health improvements for pets. Gallant’s proprietary platform utilizes mesenchymal stem cells derived from uterine tissues, a unique approach that underpins their innovative therapies.

In summary, Gallant's mission is to make stem cell therapy accessible to pets in need by creating off-the-shelf solutions that address the underlying causes of disease, moving beyond temporary symptom relief. With regulatory advancements and the anticipated FDA conditional approval for their FCGS treatment, Gallant is poised to make a significant impact on veterinary medicine, offering hope to pets and their owners alike.